March 8, 2024
What’s New Trading partners and manufacturers can use the 3911 platform in FDA’s CDER NextGen Portal (CDER NextGen) to notify FDA of illegitimate products. Question 2 […]
March 8, 2024
Disappointing phase 3 trial results of a drug approved for the treatment of amyotrophic lateral sclerosis (ALS) may prompt the manufacturer to voluntarily pull it from […]
March 8, 2024
The US Food and Drug Administration (FDA) has put off a decision expected this month on whether to approve donanemab for Alzheimer’s disease (AD). Instead, the […]
March 8, 2024
A diagnostic approach that clusters multiple tests of visual field and retinal imaging in an intense 6-month period has demonstrated the potential to identify patients likely […]
March 8, 2024
Vitamin D levels are unlikely to have an impact on the clinical features of eosinophilic esophagitis (EoE) in adults newly diagnosed with the chronic inflammatory disorder, […]
March 8, 2024
TOPLINE: Children exposed to antibiotics during birth may have an increased risk of developing autoimmune diseases in childhood, research showed. METHODOLOGY: Researchers conducted a prospective study […]
March 8, 2024
As the world grappled with the challenges of the COVID-19 pandemic, telehealth emerged as a critical tool for delivering medical care while minimizing the risk for […]
March 8, 2024
The US Food and Drug Administration (FDA) has granted breakthrough designation to an LSD-based treatment for generalized anxiety disorder (GAD) based on promising topline data from […]
March 8, 2024
In the phase 3b ELEVATE trial, preventive treatment with atogepant (Qulipta) significantly reduced monthly migraine days compared to placebo in adults with episodic migraine in whom […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674
Next page